Clinical Trials · NCT05726292
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- University of Chicago
- Enrollment
- 90
- Start date
- Jan 2025
- Locations
- 2 sites, United States
- Primary endpoint
- Response Rate of Subjects Receiving Relacorilant with Enzalutamide and Hormone Therapy